Skip to main content

Advertisement

SpringerLink
Log in

Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs—a primary or secondary entity?

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

A 54-year-old man with confirmed psoriatic arthritis, treated with conventional and biologic disease-modifying anti-rheumatic drugs, suffered from severe, recurrent respiratory tract infections. He was found to have hypogammaglobulinemia. Further investigations confirmed the diagnosis of common variable immunodeficiency. Introduction of immunoglobulin G replacement therapy allowed for safe and effective treatment of psoriatic arthritis with etanercept and methotrexate. Patients with a history of recurrent infections on disease-modifying anti-rheumatic drugs and hypogammaglobulinemia should be assessed for primary antibody immunodeficiencies, even in adulthood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS (2016) Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol 22:241–247

    Article  PubMed  PubMed Central  Google Scholar 

  2. Haroon N, Inman RD (2009) Infectious complications of biological therapy. Curr Opin Rheumatol 21:397–403

    Article  PubMed  Google Scholar 

  3. Furst DE (2009) Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 39:18–29

    Article  CAS  PubMed  Google Scholar 

  4. Blot M, Boyer P, Samson M et al (2014) Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. Eur J Intern Med 25:837–842

    Article  PubMed  Google Scholar 

  5. Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P (2011) Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine 78:241–245

    Article  PubMed  Google Scholar 

  6. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieschi C, Thorn V, Abedi MR, Hammarstrom L (2008) Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112:277–286

    Article  CAS  PubMed  Google Scholar 

  7. Gathmann B, Mahlaoui N, CEREDIH et al (2014) Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 134:116–126

    Article  PubMed  Google Scholar 

  8. ESID Working Definitions for diagnosis of PID. file:///C:/Users/Samsung/Downloads/ESIDRegistry_ClinicalCriteria%20(5).pdf

  9. Bonilla FA, Barlan I, Chapel H et al (2016) International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 4:38–59

    Article  PubMed  Google Scholar 

  10. Wirsum C, Glaser C, Gutenberger S et al (2016) Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency. J Clin Immunol 36:406–412

    Article  CAS  PubMed  Google Scholar 

  11. Makatsori M, Kiani-Alikhan S, Manson AL et al (2014) Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. QJM 107:821–828

    Article  CAS  PubMed  Google Scholar 

  12. Boileau J, Mouillot G, Gerard L et al (2011) Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun 36:25–32

    Article  CAS  PubMed  Google Scholar 

  13. Sordet C, Cantagrel A, Schaeverbeke T, Sibilia J (2005) Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine 72:503–514

    Article  PubMed  Google Scholar 

  14. Swierkot J, Lewandowicz-Uszynska A, Chlebicki A, Szmyrka-Kaczmarek M, Polańska B, Jankowski A, Szechiński J (2006) Rheumatoid arthritis in a patient with common variable immunodeficiency: difficulty in diagnosis and therapy. Clin Rheumatol 25:92–94

    Article  CAS  PubMed  Google Scholar 

  15. Lin LH, Tsai CN, Liu MF, Wang CR (2005) Common variable immunodeficiency mimicking rheumatoid arthritis with Sjögren’s syndrome. J Microbiol Immunol Infect 38:358–360

    PubMed  Google Scholar 

  16. Diamantopoulos AP, Haugeberg G (2012) Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs. Mod Rheumatol 22:295–297

    Article  PubMed  Google Scholar 

  17. Xiao X, Miao Q, Chang C, Gershwin ME, Ma X (2014) Common variable immunodeficiency and autoimmunity—an inconvenient truth. Autoimmun Rev 13:858–864

    Article  CAS  PubMed  Google Scholar 

  18. Dimitriades VR, Sorensen R (2016) Rheumatologic manifestations of primary immunodeficiency diseases. Clin Rheumatol 35:843–850

    Article  CAS  PubMed  Google Scholar 

  19. Stiehm ER, Keller MA, Vyas GN (2008) Preparation and use of therapeutic anti-bodies primarily of human origin. Biologicals 36:363–374

    Article  CAS  PubMed  Google Scholar 

  20. Bonilla FA (2016) Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 37:426–431

    Article  PubMed  Google Scholar 

  21. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H (2010) Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125:1354–1360.e4

    Article  CAS  PubMed  Google Scholar 

  22. Quinti I, Agostini C, Tabolli S, Brunetti G, Cinetto F, Pecoraro A, Spadaro G (2012) Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood 120:1953–1954

    Article  CAS  PubMed  Google Scholar 

  23. Ammann EM, Jones MP, Link BK et al (2016) Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 127:200–207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Pulmonology, Allergy and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine in Warsaw, Warsaw, Poland

    Ewa Więsik-Szewczyk, Aleksandra Kucharczyk & Karina Jahnz-Różyk

  2. Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland

    Katarzyna Świerkocka

  3. Hematology and Flow Cytometry Laboratory, Department of Internal Medicine and Hematology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine in Warsaw, Warsaw, Poland

    Elżbieta Rutkowska

Authors
  1. Ewa Więsik-Szewczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleksandra Kucharczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katarzyna Świerkocka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elżbieta Rutkowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karina Jahnz-Różyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ewa Więsik-Szewczyk.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Więsik-Szewczyk, E., Kucharczyk, A., Świerkocka, K. et al. Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs—a primary or secondary entity?. Clin Rheumatol 36, 1677–1681 (2017). https://doi.org/10.1007/s10067-017-3670-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3670-1

Keywords

Search

Navigation